Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

Not Applicable

Recruiting

Conditions: COVID-19.
Coronavirus infection, unspecified
B34.2

Registration Number: IRCT20181104041551N1

Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

COVID-19 Patients
Consent to attend the study
Do not be intubated
PaO2 / FiO2 above 200 or Spo2 above 85%

Exclusion Criteria

A history of hypersensitivity to blood transfusions or its products
History of IgA deficiency
Heart failure or any factor that prevent from getting 500ml of plasma
Entering the intubation stage

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality. Timepoint: 10 days and 30 days after intervention. Method of measurement: Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time.;Inflammatory factors. Timepoint: Days 1, 3 and 7. Method of measurement: The enzyme-linked immunosorbent assay.;Partial pressure of arterial oxygen/Percentage of inspired oxygen. Timepoint: Days 1, 3, 7. Method of measurement: Partial pressure of arterial oxygen/Percentage of inspired oxygen.

Secondary Outcome Measures

Name	Time	Method
ength of hospitalization. Timepoint: End of study. Method of measurement: Day number.;Days of mechanical ventilation. Timepoint: End of study. Method of measurement: Day number.;Leukocyte and lymphocyte count. Timepoint: Days 1, 3, 7. Method of measurement: Complete blood count test.;CD3, CD4, CD8 cell count and CD4 / CD8 ratio. Timepoint: Days 1, 3, 7. Method of measurement: Flow Cytometry.;Function and changes of liver enzymes. Timepoint: Days 1, 3, 7. Method of measurement: Biochemical tests.;Cardiac enzyme function and changes. Timepoint: Days 1, 3, 7. Method of measurement: Biochemical tests.;Specific IgG. Timepoint: Days 1, 3, 7. Method of measurement: The enzyme-linked immunosorbent assay.;Radiological findings. Timepoint: Admitted time and day 14. Method of measurement: Computed tomography Scan and Chest X-Ray.